Call for proposals to support the development of innovative medical countermeasures for chemical, biological, radiological and nuclear threats (HERA) - Medicinal products
Forecasted
Funds innovative research to develop vaccines and treatments for chemical, biological, radiological, and nuclear threats to improve EU health security and preparedness.
This grant is no longer accepting proposals
European Commission has archived this opportunity.
Funder: European Commission
Due Dates (Anticipated): December 2026 (full application submission, projected)
Funding Amounts: €18,000,000 total for this topic; typical project budget €5.5–9 million; project duration 24–48 months; funding rate 60% (up to 80% for exceptional utility)
Summary: Supports advanced research and development of innovative medical countermeasures to enhance EU preparedness against chemical, biological, radiological, and nuclear (CBRN) threats.
Key Information: This is a forecasted call—dates and details may change; check the program page for updates.
Description
This anticipated call supports the development of innovative medical countermeasures targeting chemical, biological, radiological, and nuclear (CBRN) threats, as part of the EU4Health Programme (EU4H) and managed by the European Health and Digital Executive Agency (HaDEA) in collaboration with HERA. The goal is to improve the European Union’s readiness to respond to intentional and cross-border health threats by advancing vaccines, therapeutics, antidotes, supportive treatments, and platform technologies that address CBRN agents for which there are currently no or limited treatment options. Projects should bridge advanced research, innovation, market access, and deployment, and bring products closer to regulatory approval and market readiness.
The call specifically targets medicinal products (sub-topic a), including vaccines and therapeutics against biological, chemical, and radio-nuclear threats. Proposals should involve end users and security practitioners to ensure practical relevance and market viability.
